Dynamic transcriptional responses to trametinib and current standard-of-care anti-HER2 therapies in TNBC and HER2+ breast cancers with 1 week of treatment showed the rapid change in interconvertible phenotypic states of the tumor cell in patients. This evidence concerns the gene ERBB2 and breast cancer.